Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

Novartis

Status and phase: Completed; Phase 3

Conditions: Alzheimer's Disease; Dementia, Alzheimer Type

Treatments: Drug: rivastigmine transdermal patch

Study type: Interventional

Funder types: Industry

Identifiers

NCT00099242

CENA713D2320

Details and patient eligibility

About

The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.

Sex: All

Ages: 50 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of dementia of the Alzheimer's type
• Males, and females who are surgically sterile or one year postmenopausal
• A primary caregiver willing to accept responsibility for supervising the treatment

Exclusion criteria

• Any condition (other than Alzheimer's) that could explain patient's dementia
• An advanced, severe or unstable disease that may put the patient at special risk
• Current diagnosis of active, uncontrolled seizure disorder or unstable cardiovascular disease

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind